TRAF3IP2

Across TCGA pan-cancer cohorts, TRAF3IP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAF3IP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TRAF3IP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRAF3IP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and UCEC are the cancer types where TRAF3IP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.833	0.323	.001	14	view →
PDAC	DFS	Median	III,IV	0.949	0.306	.006	6	view →
UCEC	DFS	Tertile	All	0.941	0.755	.016	6	view →
LUAD	OS	Quartile	III,IV	0.815	0.322	.034	2	view →
LSCC	DFS	Quartile	All	1.000	0.886	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAF3IP2–GBM (DFS)

Open the GBM breakdown →